StockData

Korsana Biosciences vs NRX Pharmaceuticals

KRSA and NRXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRSA and NRXP compare

Korsana Biosciences is the larger company, worth 1.4 times as much as NRX Pharmaceuticals ($152M against $106M).

Korsana Biosciences keeps more of each dollar of sales as profit, with a net margin of −353% compared with −692% at NRX Pharmaceuticals.

Korsana Biosciences scores higher on the StockData Score (6 against 0 for NRX Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRSANRXP
Size and price
Market cap$152M$106M
Share price$32.50$2.45
Change, 1 year241%−1.6%
Change, 5 years−90.5%−96.4%
Beta (5Y)5.731.15
Employees129
StockData Score
Total score6 (better)0
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score4 (better)0
Dividend score00
Valuation
P/S80.1×31.3× (better)
P/B29.9×–
Fair value$5.48–
Margin of safety−493%–
Growth
Revenue growth (TTM)−12.6%–
Revenue growth, 5Y average−2.0%–
Profitability
Gross margin–46.6%
Operating margin−359% (better)−586%
Net margin−353% (better)−692%
Return on equity−98.2%–
Return on invested capital−116%–
Financial health
Debt / equity0.00–
Interest coverage–−17.4×
Current ratio0.820.86 (better)
Altman Z-score−9.25 (better)−13.45
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions15.1%26.9%
Held by insiders–15.6%
Short interest, % of float–28.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.